GCG and type 1 diabetes mellitus: The proposed method will also allow, for the first time, to precisely determine the key paracrine interaction, its dysregulation and help develop an explicit glucagon model for testing in the FDA-approved T1D simulator [17, 18] prior to clinical trials.